Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote & News

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 967 6677

Website: citiuspharma.com

Address:

11 Commerce Drive, First Floor, Cranford, United States

SweStonk Oct. 24 at 1:36 PM

$CTXR gonna create even more bagholders! CTXR is worthless. He have been trying to sell Halo for years. They tried to sell ML to CRMD they said NO thank you. Only thing left is share distribution but the dilution have destroyed the value from it.

0 · Reply

Mapletreet Oct. 24 at 1:28 PM

$CTXR Celebrating 🥳

0 · Reply

Jonesstock Oct. 24 at 1:05 PM

$CTXR idk when but I will get my money back

1 · Reply

SweStonk Oct. 24 at 11:23 AM

$CTXR We will distribute the shares. We will distribute a portion of the shares. 2026 We wont distribute the shares. He will never leave the control of CTOR. It is his lifeboat and he will continue to dilute CTXR until it is completely drained.

0 · Reply

SweStonk Oct. 23 at 10:11 PM

$CTXR You will only get a portion of the shares 😂 He said he would distribute but not how much. He is bout to turn CTXR to a holding company.

1 · Reply

TwongStocks Oct. 23 at 9:13 PM

$CTXR Updated investor slides https://s28.q4cdn.com/169506891/files/doc_presentations/2025/Oct/23/CTXR-Corporate-Overview-OCT-2025-FINAL.pdf

0 · Reply

TwongStocks Oct. 23 at 3:48 PM

$CTOR $CTXR My favorite is when two people get in an an argument, but instead of keeping that argument in a single thread, they just continually quote each other.

2 · Reply

SweStonk Oct. 23 at 3:44 PM

$CTOR $CTXR Still 0 counter arguments to why anyone would be bullish. Atleast I give arguments to why Im bearish. You invest here for what? Third in line treatment that will bring 10m/y. They be lucky to get a couple patients on an already small patient population.

1 · Reply

BALUGA825 Oct. 23 at 2:49 PM

$CTOR $CTXR So str8 up bashing this stock to get a discount. GOT IT!

1 · Reply

BALUGA825 Oct. 22 at 9:47 PM

$CTOR $CTXR LoL Why would they beleive you held and sold ? Contradicting your post all the time. Your full of shit!

1 · Reply

Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 21, 2025, 8:16 AM EDT - 4 days ago

PACCAR Posts Downbeat Earnings, Joins Neuphoria Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

NEUP PCAR

Oct 21, 2025, 8:00 AM EDT - 4 days ago

Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 17, 2025, 5:00 PM EDT - 7 days ago

Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences

CTOR

Oct 16, 2025, 8:47 AM EDT - 9 days ago

Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™

CTOR

Sep 10, 2025, 4:30 PM EDT - 6 weeks ago

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

Sep 9, 2025, 8:30 AM EDT - 6 weeks ago

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

CTOR

Aug 22, 2025, 8:47 AM EDT - 2 months ago

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch

CTOR

Aug 12, 2025, 4:30 PM EDT - 2 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Jul 17, 2025, 4:30 PM EDT - 3 months ago

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTOR

Jul 16, 2025, 9:15 AM EDT - 3 months ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTOR

Jul 15, 2025, 8:32 AM EDT - 3 months ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTOR

Jul 8, 2025, 8:34 AM EDT - 3 months ago

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 17, 2025, 8:08 AM EDT - 4 months ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTOR

Jun 12, 2025, 8:35 AM EDT - 4 months ago

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 10, 2025, 7:00 AM EDT - 4 months ago

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

May 14, 2025, 4:30 PM EDT - 5 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:37 AM EDT - 6 months ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTOR

Apr 1, 2025, 9:00 AM EDT - 7 months ago

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Feb 14, 2025, 4:30 PM EST - 9 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTOR

Feb 6, 2025, 8:55 AM EST - 9 months ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTOR

Jan 8, 2025, 8:00 AM EST - 10 months ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 7, 2025, 8:08 AM EST - 10 months ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTOR

Jan 6, 2025, 7:50 AM EST - 10 months ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTOR

Dec 27, 2024, 5:00 PM EST - 10 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Nov 25, 2024, 8:03 AM EST - 11 months ago

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Nov 22, 2024, 9:00 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Nov 18, 2024, 4:05 PM EST - 1 year ago

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Nov 15, 2024, 1:30 PM EST - 1 year ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Nov 11, 2024, 8:45 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Sep 5, 2024, 4:30 PM EDT - 1 year ago

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Aug 12, 2024, 5:28 PM EDT - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:22 PM EDT - 1 year ago

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

$Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Aug 8, 2024, 6:59 AM EDT - 1 year ago

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

Jul 18, 2024, 7:00 AM EDT - 1 year ago

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Analysts Hunt for Undervalued Biotech Stocks

Jul 11, 2024, 11:00 AM EDT - 1 year ago

Bloodstream Infections - From Threats to Solutions

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Biopharma Stocks Transformative Innovation for the Future of Health

Jul 10, 2024, 9:10 AM EDT - 1 year ago

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

May 29, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

May 21, 2024, 7:00 AM EDT - 1 year ago

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

May 14, 2024, 4:05 PM EDT - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

Apr 26, 2024, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

SweStonk Oct. 24 at 1:36 PM

0 · Reply

Mapletreet Oct. 24 at 1:28 PM

$CTXR Celebrating 🥳

0 · Reply

Jonesstock Oct. 24 at 1:05 PM

$CTXR idk when but I will get my money back

1 · Reply

SweStonk Oct. 24 at 11:23 AM

0 · Reply

SweStonk Oct. 23 at 10:11 PM

$CTXR You will only get a portion of the shares 😂 He said he would distribute but not how much. He is bout to turn CTXR to a holding company.

1 · Reply

TwongStocks Oct. 23 at 9:13 PM

$CTXR Updated investor slides https://s28.q4cdn.com/169506891/files/doc_presentations/2025/Oct/23/CTXR-Corporate-Overview-OCT-2025-FINAL.pdf

0 · Reply

TwongStocks Oct. 23 at 3:48 PM

$CTOR $CTXR My favorite is when two people get in an an argument, but instead of keeping that argument in a single thread, they just continually quote each other.

2 · Reply

SweStonk Oct. 23 at 3:44 PM

1 · Reply

BALUGA825 Oct. 23 at 2:49 PM

$CTOR $CTXR So str8 up bashing this stock to get a discount. GOT IT!

1 · Reply

BALUGA825 Oct. 22 at 9:47 PM

$CTOR $CTXR LoL Why would they beleive you held and sold ? Contradicting your post all the time. Your full of shit!

1 · Reply

SweStonk Oct. 22 at 8:03 PM

$CTOR $CTXR You should read before comment. You should re read before sharing. I have no position here. Sold @ ~$2.1 on CTXR and ~$2.66 on CTOR. Mazur will never give up CTOR. If he distribute he wont have full control. When he choose to sell ML and not the company it is clear as day. Why do you think the SP have dropped this much after the conference? Why Mazur didnt hold the conference? Some people really want nothing more than to blow their portfolio..... SAVA all over this.

0 · Reply

NYC100 Oct. 22 at 6:56 PM

$CTOR $CTXR I think you should sell it if you’re so afraid

1 · Reply

SweStonk Oct. 22 at 5:54 PM

$CTOR $CTXR He about to fuck every investor in CTXR. Selling the main asset and not the company(CTXR) and already spun off the other asset(lymphir) is very bad news. CTXR will be worthless and only a holding company while management benefit from getting free shares in CTOR. There are only a handful of companies that have done this before and they all went bankrupt. This is very bad news. When trust is gone so is the company. What makes you think it will be different in CTOR? After investors know what he have done why would anyone trust him with their own money? I have waited for an opportunity to enter cheaper because of ML but this is very very slimy of him. Their estimates are completely off for Lymphir and it seems they are trying to blow up the value. Competition with more patients and better efficiancy dont have revenue anywhere near their estimates. Never thought in my life that applebot was about to be correct about all of this.

0 · Reply

SweStonk Oct. 22 at 5:38 PM

$CTXR No wonder for the first time in 5 years that Mazur dont hold the conference. They never said that they will sell CTXR but only the assets(ML and Halo). They will turn CTXR into a holding company and will distribute the shares when they are done with CTOR which is years away(or never) if we gonna follow the recent shares award for Mazur and his buddies. By doing this CTXR will be worthless. Only a few companies have ever done this before and they all went bankrupt. When trust is gone from the investors so is the company. Selling your only asset instead of the company(CTXR) is relly really bad news for every investor here. This is not like any regular BO.

0 · Reply

st0ckt1cker Oct. 22 at 2:06 PM

$CTXR so finally a release of the drug and the stock is dropping, I just don’t get it

1 · Reply

st0ckt1cker Oct. 22 at 1:51 PM

$CTXR I honestly don’t know if I should hold or sell…damn, especially if news finally a release is upcoming

1 · Reply

Noname2022 Oct. 22 at 10:01 AM

$CRMD $CTXR Mino Lok is for sale https://www.reddit.com/r/CTXR/comments/1oclm08/recap_ld_micro_main_event_oct_21/

6 · Reply

BALUGA825 Oct. 21 at 11:22 PM

$CTOR $CTXR Let me get this str8: FDA approved drug will be launch this month and the other d4ug on phase 3 trial will get a green light this year. Did i read that right ?

0 · Reply

SweStonk Oct. 21 at 8:51 PM

$CTXR We are supposed to trust Mazur will distribute after he sells ML? Will he give up his power in CTOR? He is banking on CTOR and have planned 5 years ahead of printing free sharea to himself. Seems like Applebot was correct about Mazurs lifeboat and CTXR will turn to a holding company. He wont distribute anything until he is able to sell CTOR which is years away.

0 · Reply

TwongStocks Oct. 21 at 8:51 PM

$CTXR SEC filing confirms a 90 day lockup. One exception is that they can use the ATM after 30 days, but only above $2.15 https://www.sec.gov/ix?doc=/Archives/edgar/data/1506251/000121390025100847/ea0261909-8k_citius.htm "Pursuant to the Purchase Agreement, the Company agreed for a period of 90 days following the closing of the Offering not to issue, enter into an agreement to issue or announce the issuance or proposed issuance of the shares or any other securities convertible into, or exercisable or exchangeable for, shares of common stock, subject to certain exceptions; provided that after 30 days after closing, the Company may issue shares of common stock in an “at the market” offering with the placement agent as sales agent at an offering price equal to or greater than $2.15 per share." Earliest $CTOR can raise again is Nov 14, when the lockup from their Sept offering expires. Earliest CTXR can raise again is Jan 19, 2026, ninety days from today.

1 · Reply

GJ_Rockabilt Oct. 21 at 7:39 PM

$CTXR I'll keep watch of this to see where Halo-Lido ends up, after it gets sold off. I'm done trying to follow the shill.

0 · Reply

TwongStocks Oct. 21 at 7:00 PM

$CTXR $CTOR Recap of today's presentation. Interestingly, Leonard did not give the presentation. This was Paul Sowyrda, VP of Business Development & Market Intelligence. LYMPHIR • During the Q&A, he stated that they were planning to launch LYMPHIR by the end of the month • In process of signing additional international agreements for LYMPHIR, plan to cover 38 countries by EoY. Price of drug in US is expected to be $326,000 per patient per year • Expect year initial sales to be under $100M in first 12 months, profitable within first 9 months. Year 4 sales expected to be $400M • Trial combining LYMPHIR with KEYTRUDA: seeing 40% ORR in in-stage GYN cancers & they are in mature discusssions with Merck • Trial combining LYMPHIR with CAR-T: seeing 91% resposne rates in refractory B-cell lymphomas • CTOR has 18 months of LYMPHIR in inventory. CTOR raised $9M last month, will be doing another raise in the next few weeks to support the commercial launch More in comments

4 · Reply

Market Cap	29.26M
Revenue (ttm)	0.00
Net Income (ttm)	-39.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	878,800
Avg Vol	863,686
Day's Range	N/A - N/A
Shares Out	17.01M
Stochastic %K	61%
Beta	1.41
Analysts	Sell
Price Target	$6.00